phrykt

Akebia Therapeutics, Inc. (AKBA): who owns it and who trades it

As of Nov 16, 2026, AKBA insiders reported 16 open-market sales worth $963K and 1 purchase worth $86.6K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was John P. Butler (CEO), with $474K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Akebia Therapeutics

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, AKBA insiders reported $86.6K of open-market purchases and $963K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$86.6K
1 trades, 1 people
Sales, 12 months
$963K
16 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jun 29, 2026
Filed Jul 1, 2026

Purchases and sales by month

$901K$901KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 29, 2026Erik OstrowskiCFOSale56,019$1.11$62.2KForm 4
Mar 4, 2026John P. ButlerCEOPurchase69,270$1.25$86.6KForm 4
Feb 2, 2026Richard C MalabreVice presidentSale13,382$1.39$18.6KForm 4
Feb 2, 2026Richard C MalabreVice presidentSale36,142$1.39$50.2KForm 4
Feb 2, 2026Nicholas GrundChief Commercial OfficerSale53,585$1.39$74.5KForm 4
Feb 2, 2026Nicholas GrundChief Commercial OfficerSale31,244$1.39$43.4KForm 4
Feb 2, 2026Steven Keith BurkeVice presidentSale25,375$1.39$35.3KForm 4
Feb 2, 2026Steven Keith BurkeVice presidentSale21,582$1.39$30KForm 4
Feb 2, 2026Steven Keith BurkeVice presidentSale20,701$1.39$28.8KForm 4
Feb 2, 2026Carolyn M. RucciVice presidentSale16,846$1.39$23.4KForm 4
Feb 2, 2026Carolyn M. RucciVice presidentSale25,382$1.39$35.3KForm 4
Feb 2, 2026Carolyn M. RucciVice presidentSale27,544$1.39$38.3KForm 4
Feb 2, 2026Erik OstrowskiCFOSale34,951$1.39$48.6KForm 4
Feb 2, 2026John P. ButlerCEOSale83,689$1.39$116KForm 4
Feb 2, 2026John P. ButlerCEOSale114,891$1.39$160KForm 4
Feb 2, 2026John P. ButlerCEOSale96,065$1.39$134KForm 4
Feb 2, 2026John P. ButlerCEOSale46,660$1.39$64.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
John P. ButlerCEO and President, Director$86.6K$474KMar 4, 2026
Nicholas GrundChief Commercial Officer–$118KFeb 2, 2026
Erik OstrowskiSVP, CFO, CBO & Treasurer–$111KJun 29, 2026
Carolyn M. RucciSVP, Chief Legal Officer–$97KFeb 2, 2026
Steven Keith BurkeSVP, Chief Medical Officer–$94KFeb 2, 2026
Richard C MalabreSVP, Chief Accounting Officer–$68.8KFeb 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AKBA short interest

Moderate short interest. 9.8% of AKBA shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 3%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 27.20M AKBA shares were sold short, 9.8% of the shares outstanding, up 17.9% from the report before. At the average daily volume of 9.05M shares, buying them all back would take about 3.0 trading days (days to cover).

Shares short, % of all shares

9.82%May 15Oct 3011.5%

Days to cover

3.0May 15Oct 309.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202627.20M9.82%+18%9.05M3.0
Oct 15, 202623.07M8.33%+3%7.79M3.0
Sep 30, 202622.48M8.11%+10%6.41M3.5
Sep 15, 202620.50M7.40%-11%7.44M2.8
Aug 31, 202623.00M8.30%+8%9.83M2.3
Aug 14, 202621.37M7.71%+11%6.04M3.5
Jul 31, 202619.18M6.92%+1%2.18M8.8
Jul 15, 202619.08M7.11%-1%4.54M4.2
Jun 30, 202619.18M7.15%-34%7.12M2.7
Jun 15, 202629.20M10.89%+6%5.21M5.6
May 29, 202627.42M10.22%+4%6.62M4.1
May 15, 202626.37M9.83%-5%4.64M5.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Akebia Therapeutics company events

Akebia Therapeutics filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 23, 2026ListingAkebia Therapeutics, Inc. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.00001 per share, had closed below $1.00 per… Filing
  3. Oct 14, 2026LeadershipNicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, Inc., notified the Company of his decision to resign his employment with the Company for personal reasons. Filing
  4. Aug 5, 2026ResultsReleased financial results. Filing
  5. Jun 30, 2026AnnouncementThe Company and USRC announced the results of a planned interim analysis of the VOICE trial and that it met the predefined stopping criteria by establishing non-inferiority and superiority of the primary composite endpoint and the decision by USRC Kidney Research to stop the trial on this basis. Filing
  6. Jun 22, 2026VoteReported shareholder vote results. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Apr 1, 2026LeadershipReported a change among its top officers or directors, or their pay. Filing
  9. Feb 26, 2026ResultsReleased financial results. Filing
  10. Jan 30, 2026LeadershipThe Company entered into an amended and restated executive severance agreement with the Company’s President and Chief Executive Officer, John P. Butler. Filing
  11. Jan 12, 2026ResultsReleased financial results. Filing
  12. Dec 1, 2025AgreementAkebia Therapeutics, Inc. entered into an Asset Purchase Agreement with Q32 Bio Inc. and Q32 Bio Operations Inc. (together, “Q32”), pursuant to which Q32 sold and assigned to the Company, and the Company purchased and assumed from Q32, substantially all assets and liabilities of Q32 and its… Filing
  13. Nov 17, 2025AgreementAs previously disclosed, on May 24, 2023, Akebia Therapeutics, Inc. and MEDICE Arzneimittel Putter GmbH & Co. KG entered into a License Agreement pursuant to which the Company granted to Medice an exclusive license to develop and commercialize Vafseo for the treatment of anemia in patients with… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Akebia Therapeutics financials

Famous investors that hold AKBA

4 of the 50 well-known investors we track reported holding AKBA in their latest 13F filing. The largest position is Jim Simons's, worth $1.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.88M$1.7M0.0%+54%
Israel Englander · Millennium ManagementQ3 20261.79M$1.6M0.0%-44%
Steve Cohen · Point72 Asset ManagementQ3 20261.33M$1.2M0.0%New
Ken Griffin · Citadel AdvisorsQ3 20261.04M$958K0.0%-39%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Akebia Therapeutics, Inc. (AKBA) stock

Are AKBA insiders buying or selling?

In the last 12 months, AKBA insiders reported 1 open-market purchase worth $86.6K and 16 sales worth $963K. The latest trade was on Jun 29, 2026. See every trade.

What is the short interest in AKBA?

As of Oct 30, 2026, 27.20M AKBA shares were sold short, 9.8% of the shares outstanding, up 17.9% from the report before. At the average daily volume of 9.05M shares, buying them all back would take about 3.0 trading days (days to cover). See the history.

Which famous investors hold AKBA?

4 of the 50 well-known investors we track reported AKBA in their latest 13F filing, including Jim Simons, Israel Englander, Steve Cohen. The largest position is worth $1.7M. See all holders.

Executive pay

Akebia Therapeutics's chief executive was paid a total of $5.7M for the year ended Dec 31, 2025, up 33% from $4.3M the year before. In the last 12 months, Akebia Therapeutics's executives and directors bought $86.6K of stock on the open market and sold $963K.

Chief executive, total pay$5.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$4.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.